title: Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.
abstract: Strategies to enhance the already established doublet chemotherapy regimen for lung cancer have been investigated for more than 20 years. Initially, the concept was to administer chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active transport by using pharmaceuticals designed to target the genome of tumors. In the present study, five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative stage IIIa-IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy using combined intratumoral-regional and intravenous route of administration. Cisplatin analogues were injected at 0.5%-1% concentration within the tumor lesion and proven malignant lymph nodes according to pretreatment histological/cytological results and the concentration of systemic infusion was decreased to 70% of a standard protocol. This combined intravenous plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of patients. To the best of our knowledge this is the first report of direct treatment of involved lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without any adverse effects. The initial overall survival and local response are suggestive of a better efficacy compared to established doublet cisplatin-based systemic chemotherapy in (higher) standard concentrations alone according to the UICC 7 database expected survival. An extensive search of the literature was performed to gather information of previously published literature of intratumoral chemo-drug administration and formulation for this treatment modality. Our study shows a favorable local response, more than a 50% reduction, for a massive tumor mass after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose intravenous chemotherapy according to our protocol. These encouraging results (even in very sick ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis [TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the way for broader applications of this technique. Finally, future perspectives of this treatment and pharmaceutical design for intratumoral administration are presented.
authors.affiliation: II Medical Clinic, Coburg Hospital, University of Wuerzburg, Coburg, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hohenforst-Schmidt
authors.forename: Paul
authors.initials: P
authors.lastname: Zarogoulidis
authors.forename: Kaid
authors.initials: K
authors.lastname: Darwiche
authors.forename: Thomas
authors.initials: T
authors.lastname: Vogl
authors.forename: Eugene P
authors.initials: EP
authors.lastname: Goldberg
authors.forename: Haidong
authors.initials: H
authors.lastname: Huang
authors.forename: Michael
authors.initials: M
authors.lastname: Simoff
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Robert
authors.initials: R
authors.lastname: Browning
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Turner
authors.forename: Patrick
authors.initials: P
authors.lastname: Le Pivert
authors.forename: Dionysios
authors.initials: D
authors.lastname: Spyratos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Zarogoulidis
authors.forename: Seyhan I
authors.initials: SI
authors.lastname: Celikoglu
authors.forename: Firuz
authors.initials: F
authors.lastname: Celikoglu
authors.forename: Johannes
authors.initials: J
authors.lastname: Brachmann
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001707:Biopsy, Needle; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging
chemical_list: D000970:Antineoplastic Agents
keywords: chemotherapy; cisplatin; intratumoral; lung cancer; lymph nodes
references.citation: Clin Dev Immunol. 2011;2011:134020
references.pmid: 22162709
references.citation: Br J Cancer. 2002 Oct 21;87(9):938-44
references.pmid: 12434280
references.citation: Gastrointest Endosc. 2012 Feb;75(2):332-8
references.pmid: 22248601
references.citation: Monaldi Arch Chest Dis. 1996 Aug;51(4):325-8
references.pmid: 8909019
references.citation: Phys Med Biol. 2007 Aug 21;52(16):5025-42
references.pmid: 17671351
references.citation: Cancer Immunol Immunother. 2009 Oct;58(10):1557-63
references.pmid: 19184001
references.citation: ACS Nano. 2012 May 22;6(5):4157-68
references.pmid: 22486623
references.citation: J Exp Clin Cancer Res. 2011 Oct 24;30:101
references.pmid: 22024187
references.citation: Lung Cancer. 2012 Apr;76(1):84-8
references.pmid: 22018594
references.citation: J Clin Oncol. 2007 Sep 10;25(26):4043-50
references.pmid: 17827452
references.citation: PLoS One. 2013;8(3):e55917
references.pmid: 23520448
references.citation: PLoS One. 2012;7(6):e38150
references.pmid: 22761669
references.citation: Lung Cancer. 2006 Dec;54(3):339-46
references.pmid: 17045361
references.citation: J Multidiscip Healthc. 2012;5:47-51
references.pmid: 22396625
references.citation: Future Oncol. 2013 Apr;9(4):505-25
references.pmid: 23560374
references.citation: Mutat Res. 2012 Dec;740(1-2):1-5
references.pmid: 23116732
references.citation: PLoS One. 2011;6(10):e26413
references.pmid: 22039482
references.citation: J Korean Med Sci. 2011 Oct;26(10):1270-6
references.pmid: 22022177
references.citation: Anticancer Drugs. 2009 Oct;20(9):838-44
references.pmid: 19668080
references.citation: Technol Cancer Res Treat. 2009 Jun;8(3):207-16
references.pmid: 19445538
references.citation: Carcinogenesis. 2006 Sep;27(9):1729-38
references.pmid: 16597644
references.citation: Pharmacogenomics. 2012 Jul;13(9):1073-86
references.pmid: 22838953
references.citation: Onco Targets Ther. 2013;6:125-34
references.pmid: 23467839
references.citation: Cancer Sci. 2012 Mar;103(3):535-41
references.pmid: 22145952
references.citation: Radiology. 2010 Dec;257(3):685-96
references.pmid: 20858851
references.citation: J Pharm Pharmacol. 2002 Feb;54(2):159-80
references.pmid: 11848280
references.citation: Ther Deliv. 2012 Aug;3(8):933-6
references.pmid: 22946427
references.citation: Transl Res. 2012 Jan;159(1):32-41
references.pmid: 22153808
references.citation: Cancer Res. 2012 Mar 15;72(6):1485-93
references.pmid: 22282664
references.citation: Cancer Res. 2011 Feb 1;71(3):686-92
references.pmid: 21123454
references.citation: Eur J Cardiothorac Surg. 2003 May;23(5):824-7
references.pmid: 12754040
references.citation: J Pharm Pharmacol. 2003 Oct;55(10):1441-8
references.pmid: 14607028
references.citation: Int J Pharm. 2012 Apr 4;425(1-2):19-28
references.pmid: 22265915
references.citation: Lung Cancer. 1996 Sep;15(2):197-205
references.pmid: 8882986
references.citation: Postgrad Med J. 1997 Mar;73(857):159-62
references.pmid: 9135832
references.citation: Pharmacogenomics. 2012 May;13(7):789-802
references.pmid: 22594511
references.citation: ScientificWorldJournal. 2012;2012:126723
references.pmid: 22629119
references.citation: Int J Nanomedicine. 2013;8:1051-62
references.pmid: 23515368
references.citation: Invest New Drugs. 2012 Aug;30(4):1628-40
references.pmid: 21739158
references.citation: Int J Pharm. 2012 Jul 1;430(1-2):350-8
references.pmid: 22525076
references.citation: J Immunol. 2012 Sep 1;189(5):2656-64
references.pmid: 22844125
references.citation: Int J Nanomedicine. 2012;7:1551-72
references.pmid: 22619512
references.citation: Lung Cancer. 2006 Feb;51(2):225-36
references.pmid: 16359751
references.citation: BMC Cancer. 2011 Mar 31;11:117
references.pmid: 21453495
references.citation: PLoS One. 2011;6(12):e29020
references.pmid: 22216160
references.citation: Int J Nanomedicine. 2012;7:1697-708
references.pmid: 22619520
references.citation: Lung Cancer. 2008 Jul;61(1):1-12
references.pmid: 18455832
references.citation: Zhonghua Jie He He Hu Xi Za Zhi. 2000 Sep;23(9):550-1
references.pmid: 11778530
references.citation: Nihon Kyobu Shikkan Gakkai Zasshi. 1982 Feb;20(2):170-5
references.pmid: 7098181
references.citation: Support Care Cancer. 2013 Jun;21(6):1665-75
references.pmid: 23338228
references.citation: Chem Phys Lipids. 2012 May;165(4):424-37
references.pmid: 22197685
references.citation: J Natl Cancer Inst. 1996 Sep 4;88(17):1193-203
references.pmid: 8780628
references.citation: J Pharm Pharmacol. 2010 Mar;62(3):287-95
references.pmid: 20487210
references.citation: Cancer Gene Ther. 2012 Jun;19(6):374-81
references.pmid: 22498722
references.citation: Crit Rev Oncol Hematol. 1993 Oct;15(2):91-8
references.pmid: 8117417
references.citation: Syst Synth Biol. 2010 Dec;4(4):293-7
references.pmid: 22132056
references.citation: Am J Clin Oncol. 2000 Aug;23(4):386-92
references.pmid: 10955870
references.citation: Cancer Gene Ther. 2012 Sep;19(9):593-600
references.pmid: 22744209
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62
references.pmid: 17875775
references.citation: BMC Cancer. 2012 Mar 21;12:99
references.pmid: 22436661
references.citation: PLoS One. 2011 May 03;6(5):e18758
references.pmid: 21559281
references.citation: Nano Lett. 2012 Apr 11;12(4):2165-70
references.pmid: 22417133
references.citation: Thorax. 2004 Sep;59(9):790-3
references.pmid: 15333857
references.citation: Cancer Res. 2005 Dec 15;65(24):11631-8
references.pmid: 16357174
references.citation: Eur J Pharm Biopharm. 2012 Nov;82(3):545-53
references.pmid: 22995703
references.citation: Int J Nanomedicine. 2011;6:3087-98
references.pmid: 22163162
references.citation: Clin Exp Dermatol. 2012 Mar;37(2):193-4
references.pmid: 21883396
references.citation: Chest. 1997 Oct;112(4 Suppl):203S-205S
references.pmid: 9337289
references.citation: Mol Pharm. 2012 Mar 5;9(3):514-22
references.pmid: 22332810
references.citation: Biomaterials. 2013 Mar;34(9):2277-88
references.pmid: 23290525
references.citation: Expert Opin Drug Deliv. 2012 Jul;9(7):767-81
references.pmid: 22554018
references.citation: Oncologist. 2005 Jan;10(1):34-51
references.pmid: 15632251
references.citation: Pharmacogenomics J. 2012 Aug;12(4):277-86
references.pmid: 22760589
references.citation: Biomaterials. 2012 Mar;33(8):2570-82
references.pmid: 22192536
references.citation: Int J Nanomedicine. 2012;7:2227-38
references.pmid: 22619558
references.citation: J Clin Oncol. 2006 Apr 10;24(11):1689-99
references.pmid: 16505415
references.citation: Yonsei Med J. 2013 Jan 1;54(1):1-14
references.pmid: 23225792
references.citation: Rinsho Byori. 2012 Oct;60(10):967-8
references.pmid: 23323461
references.citation: Ann N Y Acad Sci. 2002 Dec;979:159-65; discussion 188-96
references.pmid: 12543725
references.citation: Nature. 2005 Dec 15;438(7070):946-53
references.pmid: 16355212
references.citation: PLoS One. 2012;7(2):e26331
references.pmid: 22347360
references.citation: J Control Release. 2010 Jul 1;145(1):17-25
references.pmid: 20307599
references.citation: J Immunother. 2012 Oct;35(8):607-14
references.pmid: 22996366
references.citation: Transl Lung Cancer Res. 2013 Aug;2(4):256-8
references.pmid: 25806240
references.citation: J Immunother. 2012 Sep;35(7):534-43
references.pmid: 22892450